Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

An unusual tussle over the availability of funds for Apple Tree’s startups led the firm to seek protection from creditors ...

Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

The agency gave the green light to a U.S. company manufacturing Augmentin XR, an antibiotic first approved more than two ...

Hemophilia gene therapies arrived a few years ago with blockbuster expectations. But now, one therapy has been pulled from ...

A high-stakes meeting with wide-ranging public health implications again didn’t result in a vote, as members struggled to ...

Data from the "ADEPT-2" study, which analysts had hoped would arrive before year's end, are now expected sometime in 2026.

The data and AI algorithms within companion apps can help HCPs provide a diagnosis quicker, allowing them to compare their ...

CAR-T cancer therapies now need to succeed in randomized, controlled trials to earn approvals. Elsewhere, a drug from Bristol ...

Weeks after being named head of CDER, Pazdur has submitted paperwork to step down at the end of the month, exacerbating ...

A decades-old way to bridge buyers and sellers on price, contingent value rights have recently seen an uptick in use due to a ...